Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and ...

The company signed the agreement with Karolinska Institutet's Department of Cell and Molecular Biology professor Johan ...

SAN DIEGO--(BUSINESS WIRE)--Kenai Therapeutics, a biotechnology company leveraging induced pluripotent ... to developing restorative cell therapies for Parkinson’s disease and other neurological ...

SAN DIEGO — Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC ... on its innovative approach to developing restorative cell therapies for Parkinson’s disease ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell ... to developing restorative cell therapies for Parkinson’s disease and other neurological diseases.

aNSC: Adult neural stem cell; BM: Bone marrow ... in the striatum can improve motor symptoms in animal models and Parkinson's disease (PD) patients. Open-label clinical studies using fetal ...

Parkinson's disease ... for the disease. Sources for such cells are varied and include the developing ventral mesencephalon, several autologous somatic cell types, embryonic stem cells and ...

Human induced pluripotent stem cells (iPSCs) can be derived directly from adult ... two cell types implicated in Alzheimer’s ...